Endothelial activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans-signalling: a novel target for systemic sclerosis? by Barnes, Theresa C et al.
Extended report
Ann Rheum Dis 2011;70:366–372. doi:10.1136/ard.2010.133587  366
Accepted 16 September 2010
Published Online First 
10 November 2010
  ABSTRACT 
  Objectives      Systemic sclerosis (SSc) is a connective 
tissue disease associated with signiﬁ  cant morbidity and 
mortality and generally inadequate treatment. Endothelial 
cell activation and apoptosis are thought to be pivotal in 
the pathogenesis of this disease, but the mechanisms 
that mediate this remain unknown.   
  Methods      Human dermal microvascular endothelial 
cells were cultured with healthy control neutrophils 
in the presence of 25% healthy control or SSc serum 
for 24 h. Apoptosis was measured by annexin V-FITC 
binding and endothelial cell activation was measured 
using an allophycocyanin-conjugated E-selectin antibody. 
Fluorescence was quantiﬁ  ed and localised using confocal 
microscopy.  
  Results      SSc serum resulted in signiﬁ  cantly increased 
apoptosis (p=0.006) and E-selectin expression 
(p=0.00004) in endothelial cells compared with control 
serum, effects that were critically dependent on the 
presence of neutrophils. Recombinant interleukin 6 (IL-6) 
reproduced these ﬁ  ndings. Immunodepletion of IL-6 and 
the use of an IL-6 neutralising antibody decreased the 
effect of SSc serum on E-selectin expression. Soluble 
gp130, which speciﬁ  cally blocks IL-6 trans-signalling, 
negated the effect of SSc serum on both E-selectin 
expression and apoptosis.   
  Conclusions      SSc serum induces endothelial cell 
activation and apoptosis in endothelial cell-neutrophil 
co-cultures, mediated largely by IL-6 and dependent 
on the presence of neutrophils. Together with other 
pathologically relevant effects of IL-6, these data justify 
further exploration of IL-6 as a therapeutic target in SSc.           
  INTRODUCTION 
  Systemic sclerosis (SSc) is a multisystem connective 
tissue disease characterised by ﬁ  brosis of the skin 
and internal organs and by microvascular injury. 
There is considerable morbidity and a signiﬁ  cant 
increase in mortality.    1    Despite recent develop-
ments, current treatments remain inadequate and 
therefore there is a continuing need for additional 
therapeutic strategies. 
  Endothelial cell activation and apoptosis are 
thought to be pivotal in the pathogenesis of SSc. 
Some evidence points to an increase in endothelial 
cell apoptosis, although there is a lack of in vivo 
evidence to corroborate this.    2    The University of 
California at Davis line 200 chicken, an animal 
model of SSc, consistently exhibits endothelial cell 
apoptosis in skin and internal organs from serial tis-
sue samples, preceding mononuclear cell inﬁ  ltrate 
and development of ﬁ  brosis.    3        4    
  Markers of endothelial cell activation, including 
an increase in expression of cell adhesion mol-
ecules, may be observed by immunohistochemi-
cal examination of lesional tissue samples from 
patients with SSc. An increase in the serum levels 
of soluble adhesion molecules including soluble 
intercellular adhesion molecule 1 (ICAM-1) and 
soluble E-selectin are found in SSc patients com-
pared with controls, and these correlate with tis-
sue expression of endothelial adhesion molecules 
and severity of disease manifestations.    5     –      7    
  Interleukin 6 (IL-6) is a pleiotropic cytokine that 
is increased in the serum of patients with SSc and 
correlates with markers of disease activity.    8     –      12    
Immunocytochemistry demonstrates an increase 
in the levels of IL-6 in the lesional skin of patients 
with SSc and this is associated with the late stages 
of the disease.    13    IL-6 has many functions that may 
be relevant to the pathogenesis of SSc including 
endothelial cell activation.    14    
  Neutrophils were shown by Hussein   et al      15    
to be increased in lesional biopsies of patients 
with SSc compared with controls. Others have 
explored neutrophil function in SSc, in particular 
their ability to contribute to oxidative stress by 
the production of reactive oxygen species. The 
data are contradictory and are largely limited by 
old-fashioned neutrophil isolation procedures 
which can lead to neutrophil activation.    16        17    A 
recent study has, however, shown that neutro-
phils produce less reactive oxygen species in 
vitro than control neutrophils when unstimu-
lated.    18    In agreement with this, we have found 
that   neutrophils from patients with SSc are hypo-
functional in tests of reactive oxygen species 
generation and   chemotaxis (unpublished data). 
This may reﬂ  ect in vivo stimulation and hence in 
vitro ‘  exhaustion’. Proteomic studies show that 
SSc neutrophils have increased expression of pro-
teins that are also increased on stimulation with 
lipopolysaccharide or tumour necrosis factor 
(TNF), again   indicative of neutrophil activation in 
vivo (unpublished data). 
  Activated neutrophils have the potential to 
release agents capable of endothelial injury, includ-
ing reactive oxygen species and proteases, and the 
ability to affect cytokine signalling. In order to 
explore whether neutrophils could have a role in 
endothelial cell injury in SSc, the purpose of this 
study was to determine the effects of SSc serum 
on neutrophils and their interaction with endothe-
lial cells in vitro. These experiments reveal a role 
for IL-6 in induction of endothelial cell activation 
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Images were taken using the optimum separation of emission 
spectra mode. Duplicate images were taken for each experimen-
tal variable. A z-stack of 13 images was taken over a distance of 
9.91 μm, focusing from the endothelial cells to the neutrophils. 
Images were taken using a 10× ﬂ  uar 0.5 NA objective. 
  Images were analysed using Image J software (NIH, USA). 
Images representing the maximal ﬂ  uorescence values for red and 
green ﬂ  uorescence were measured for total ﬂ  uorescence inten-
sity. Values were corrected for ﬂ  uorescence intensity of cells cul-
tured in media alone.   
  Serum  cytokine  proﬁ  ling 
  Serum concentrations of granulocyte colony-stimulating factor, 
interferon γ, granulocyte-macrophage colony-stimulating factor, 
TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-17 and IL-Ra 
were quantiﬁ  ed using a 13-plex Luminex kit.   
    Assessing the role of IL-6 in neutrophil:endothelial cell 
co-cultures 
  Heat-inactivated pooled male AB serum was ﬁ  ltered (0.4 μm ﬁ  l-
ter) and spiked with 200 pg/ml rIL-6. This was added to wells 
instead of SSc or control serum. The IL-6 concentrations used 
reﬂ  ected the levels of IL-6 found in serum samples from patients 
with SSc by Luminex. 
  In order to assess whether IL-6 played a role in the effect 
of SSc serum in neutrophil:endothelial cell co-cultures, 
three different experiments were performed. First, IL-6 was 
removed from SSc serum using a direct immunodepletion kit 
in accordance with the manufacturer’s instructions and 60% 
  immunodepletion was conﬁ  rmed by western blotting (data not 
shown). Second, the polyclonal anti-IL-6 antibody was added 
to wells at a concentration of 1:400 to neutralise IL-6 in the 
co-culture. Finally, sgp130, an inhibitor of IL-6 trans-signalling, 
was added to the wells at a concentration of 500 ng/ml.
Data analysis 
  Normality of the data was assessed using SPSS. E-selectin data 
were found to be normally distributed and therefore differences 
between means were analysed using the paired t test. Annexin 
V staining was not normally distributed and therefore differ-
ences were analysed using the Wilcoxon signed rank test. The 
strength and signiﬁ  cance of clinical correlations were described 
using the Spearman correlation coefﬁ  cient.     
  RESULTS 
  Patient characteristics are summarised in table 1 in the online 
supplement. 
    Effect of SSc serum on apoptosis and E-selectin expression in 
endothelial cell:neutrophil co-cultures 
  SSc serum resulted in greater annexin-V binding (p=0.006) and 
E-selectin (p=0.00004) expression than control serum when 
added to endothelial cell:neutrophil co-cultures (  ﬁ  gure 1  ). When 
corrected for background staining in serum-free media, control 
serum did not increase E-selectin expression whereas SSc serum 
had a 2.5-fold increase in E-selectin expression. Control serum 
had a 2.5-fold increase in annexin-V staining whereas SSc serum 
had a sevenfold increase compared with media alone. There was 
wide variation in the effects of control serum and, in particular, 
SSc serum (  ﬁ  gure 2  ).     
  Annexin-V binding was detected on both neutrophils and 
endothelial cells. E-selectin is a speciﬁ  c endothelial cell marker 
and reﬂ   ects endothelial cell activation. However, E-selectin 
and apoptosis in SSc, and highlight this cytokine as a potential 
therapeutic target.   
  METHODS 
  The study was approved by the Sefton local ethics committee 
in accordance with the Helsinki declaration. Informed written 
consent was taken from patients with SSc    19    and from healthy 
volunteers. 
  Materials 
  The following materials were used in the study: human der-
mal microvascular endothelial cells (HDMECs; Promocell, 
Heidelberg, Germany ), recombinant IL-6, soluble gp130 (sgp130; 
R&D, Minneapolis, Minnesota, USA), direct immunodepletion 
kit (Thermo, Waltham, Massachusetts, USA), polyclonal rabbit 
antihuman recombinant IL-6 (rIL-6) antibody (ab6672; Abcam, 
Cambridge, UK), Polymorphprep (Axis-Shield, Dundee, UK), 
Annexin V-FITC, mitotracker red (Invitrogen, Paisley, California, 
USA), allophycocyanin (APC)-conjugated mouse monoclonal 
antihuman E-selectin antibody (ab51241; Abcam), calcein-AM 
(Calbiochem, San Diego, California, USA).   
  Culture  of  HDMECs 
  HDMECs were cultured in 48-well plates in microvascular 
endothelial cell medium (Promocell). Cultures were used in 
passage 4–8 when they reached 90% conﬂ  uence. Under these 
conditions, cell phenotype is guaranteed up to passage 14 
(Promocell).   
  Isolation  of  neutrophils 
  Neutrophils were isolated from healthy control peripheral blood 
using Polymorphprep as described in the manufacturer’s instruc-
tions. Contaminating erythrocytes were removed using ammo-
nium chloride lysis buffer (KHCO  3   3.4 mM, NH  4  Cl 155 mM, 
EDTA 96.7 μM). Neutrophils were routinely examined for 
purity using morphological analysis of cytospins; purity was 
>95% immediately after isolation. Neutrophils were resus-
pended in microvascular endothelial cell medium supplemented 
with 2 mM glutamine at a concentration of 10  6   cells/ml.   
    Preparation of serum samples 
  Serum samples were collected in clot activating tubes 
(Vacutainer). Serum was aspirated and ﬂ   ash frozen in liquid 
nitrogen, then ﬁ  ltered (0.4 μm ﬁ  lter) to remove particulate mate-
rial that could interfere with confocal microscopy.   
    Preparation of endothelial cell:neutrophil co-cultures 
  Endothelial cell culture medium was replaced with 450 μl fresh 
medium or neutrophil suspension and 150 μl SSc or healthy 
control serum. 1.5 μl annexin V and 2.5 μl of a 1:10 dilution of 
the E-selectin antibody were added to each well. Co-cultures 
were incubated for 24 h at 37°C in a 5% CO  2   humidiﬁ  ed 
atmosphere.   
    24 h time lapse imaging 
  This is outlined in the online supplement.   
  Confocal  microscopy 
  Confocal images were taken using a LSM-710 (Zeiss Welwyn 
Garden City, Hertfordshire, UK  ) confocal microscope using 
the Zen 2009 software. Annexin V-FITC was excited using the 
488 nm laser whereas APC was excited using the 633 nm laser. 
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with mitotracker red, showed that both endothelial cells and 
neutrophils were present in the cellular aggregates (  ﬁ  gure 1E  ). 
Time lapse analyses also enabled us to show that endothelial 
cell apoptosis (as evidenced by membrane blebbing and cell 
detachment) was the initiating factor for the formation of the 
aggregates (  ﬁ  gure 1D  ). 
  Single cell cultures were also performed as controls to deter-
mine if the effects on endothelial cell apoptosis and E-selectin 
expression required the presence of neutrophils. Spontaneous 
expression in co-cultures was predominantly associated 
with cellular aggregates where it was difﬁ  cult to distinguish 
  morphologically between neutrophils and endothelial cells. 
  High magniﬁ   cation z-stacks through the cellular aggre-
gates were performed, but these could not unambiguously 
assign localised E-selectin staining to a particular cell type in 
these co-cultures. Cell-speciﬁ  c counterstaining was therefore 
used. 24-Hour time lapse image series of co-cultures, where 
endothelial cells were stained with calcein-AM and neutrophils 
  Figure  1         Systemic sclerosis (SSc) serum increases endothelial activation in neutrophil co-cultures. Human dermal microvascular endothelial cells 
were co-cultured with healthy control neutrophils for 24 h in the presence of 25% healthy control or SSc serum. Apoptosis was measured using 
annexin V-FITC (green) and E-selectin expression was measured using an allophycocyanin (APC)-conjugated monoclonal antibody (red). Confocal 
images of the effects of (A) normal serum or (B) SSc serum on the co-cultures show that the SSc serum promotes aggregation and enhanced 
apoptosis and E-selection expression (p=0.006 and 0.00004, respectively, n=17). The arrow indicates endothelial cell E-selectin expression. (C), 
(D) and (E) are images taken from time lapse movies of neutrophil:endothelial cell co-cultures in the presence of 25% SSc serum. Neutrophils were 
labelled with mitotracker (red) and endothelial cells were labelled with calcein-AM (green). (C) shows a time zero image, (D) shows an image taken 
after 1 h which shows endothelial cell blebbing and detachment (indicative of apoptosis) and (E) shows that the cellular aggregates comprise 
both endothelial cells (green) and neutrophils. Neutrophil:endothelial cell co-cultures labelled with annexin V-FITC (green) and an APC-conjugated 
monoclonal anti-E-selectin antibody (red) cultured for 24 h with (F) 25% AB serum or (G) 25% AB serum containing recombinant interleukin 6 
(200  pg/ ml).    
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  The IL-6 levels correlated signiﬁ   cantly with the levels of 
endothelial activation (ρ=0.829, p=0.042) (measured by binding 
of a PE conjugated ICAM antibody) and apoptosis (ρ=0.943, 
p=0.005) in neutrophil:endothelial cell co-cultures containing 
control or SSc serum (see ﬁ  gure 3 in online supplement). 
  The addition of rIL-6 to endothelial cell cultures containing 
heat-inactivated AB serum signiﬁ   cantly increased annexin V 
staining (p=0.008) and E-selectin (p=0.006) expression, but only 
when neutrophils were present in the co-cultures (    ﬁ  gure 3  ), 
reproducing the effects of SSc serum. Interestingly, co-cultures 
spiked with rIL-6 also induced the cell aggregates that were 
commonly seen in co-cultures with SSc serum (  ﬁ  gure 1G  ).     
    Role of IL-6 in the effect of SSc serum on neutrophil:endothelial 
cell co-cultures 
  Immunodepletion of IL-6 from SSc serum resulted in a signiﬁ  -
cant decrease in E-selectin expression in co-cultures (p=0.01), 
with levels of expression similar to those seen with control 
serum. Immunodepletion of IL-6 also decreased levels of apo-
ptosis, but this did not reach statistical signiﬁ  cance  because 
of the large variation in the effects of SSc serum on apoptosis 
(p=0.06,   ﬁ  gure 4  ).   
  IL-6 neutralisation with a polyclonal anti-IL-6 antibody 
signiﬁ   cantly abrogated the effect of SSc serum on E-selectin 
expression and apoptosis in co-cultures (p=0.005 and p=0.001, 
respectively). Neutralising antibodies had no effect on apoptosis 
levels or E-selectin expression in co-cultures containing control 
serum (  ﬁ  gure 5  ).   
  sgp130 acts as a decoy receptor, binding to sILR/IL-6 com-
plexes and preventing them from signalling through cellular 
gp130 receptor. It therefore speciﬁ  cally blocks trans-signalling 
but not signalling through the IL-6 receptor.    22    The addition 
of sgp130 reversed the effect of SSc on E-selectin expression 
(p=0.033); in neutrophil-endothelial cell co-cultures there was a 
tendency for gp130 to decrease apoptosis but this did not reach 
statistical signiﬁ  cance (p=0.06), probably because of the high 
degree of variability and the small sample size (  ﬁ  gure 6  ).       
  DISCUSSION 
  The data presented here shed important new light on the 
molecular mechanisms that underlie changes in endothelial 
levels of apoptosis in endothelial cell cultures were negligible 
even after 24 h. SSc serum did not lead to enhanced apoptosis 
or E-selectin expression in endothelial cell cultures compared 
with the effects of control serum (see ﬁ  gure 1 in online supple-
ment). In neutrophil cultures alone there was some low-level 
background E-selectin expression (presumed to be non-speciﬁ  c 
binding), but there was no difference between control and SSc 
serum samples. There was no difference in neutrophil apopto-
sis when cultured with SSc serum or control serum in neutro-
phil only cultures (see ﬁ  gure 1 in online supplement). 
  E-selectin expression (  ﬁ  gure 1G  ) was located in endothe-
lial cells (indicated by the arrow), but most of the e-selectin 
expression appeared in small mobile bodies approximately 
1–2 μm in diameter. These most likely represent endothelial 
microparticles which are generated by activated endothelial 
cells and are increased in the serum of patients with SSc.    20    In 
addition, some staining was associated with what appear to 
be neutrophils. When supernatants were removed from the 
cultures after 24 h and read on the ﬂ  ow cytometer, there was 
some staining for E-selectin in the neutrophil fraction gated 
according to typical forward and side scatter but there was 
no difference between control and SSc serum (see ﬁ  gure 2 in 
online supplement). 
  No statistically signiﬁ   cant differences were found in the 
effects on E-selectin expression and apoptosis in endothelial 
cell:neutrophil co-cultures between the serum of patients with 
limited and diffuse SSc. In addition, no signiﬁ  cant difference 
was seen between serum from patients with early and late dis-
ease when early disease was deﬁ  ned as either <12 months or 
<3 years. Disease-modifying therapy did not make any signiﬁ  -
cant difference to the effects of the serum.   
    Effects of recombinant IL-6 on neutrophil:endothelial cell 
co-cultures 
  Serum levels of IL-6 were increased in patients with SSc com-
pared with controls. The IL-6 levels were consistent with those 
reported by Radstake   et al      21    in plasma samples from a large 
cohort of patients with SSc measured by Bioplex, which is simi-
lar to the Luminex kit used in this study. However, the levels 
were higher than those previously reported in SSc serum mea-
sured by ELISA in smaller cohorts.    9    
  Figure  2         Systemic sclerosis (SSc) serum induces endothelial cell apoptosis and E-selectin expression in neutrophil co-cultures. (A) Changes in 
apoptosis and (B) changes in E-selectin expression of endothelial cells when incubated with individual control and SSc serum samples (n=17). 
While there were marked variations in responses, particularly for SSc serum, both apoptosis and E-selectin expression were signiﬁ  cantly enhanced 
after incubation with SSc serum compared with the effects of control serum. (C) Summary data shown as mean±SD values (n=17). Rel MFI, mean 
ﬂ  uorescence intensity corrected to levels in media alone.          
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in vascular disease models of SSc—for example, the Fra-2 trans-
genic mouse    23   —should also be explored, although it is impor-
tant to note that differences in mouse and human immunology 
exist which could inﬂ  uence the outcome.    24    
  Neutrophils express the IL-6 receptor (IL-6R) and may respond 
to IL-6, albeit weakly, through this signalling   pathway.    25    
Endothelial cells do not express IL-6R and are only capable of 
responding to IL-6 when this cytokine is bound to soluble IL-6R 
(sIL-6R); this complex then binds to the ubiquitously expressed 
gp130 receptor—that is, via trans-signalling. There are pools 
of sIL-6R, IL-6 and sgp130 in the circulation, the latter capable 
of preventing trans-signalling. It is therefore the balance of all 
three of these elements that dictates whether IL-6 signalling 
occurs.        
  sIL-6R is generated by two separate processes: by proteolytic 
cleavage of membrane IL-6R or by synthesis and release of an 
alternatively spliced version of the receptor.    26     –      29    Neutrophils 
are the dominant source of sIL-6R in the serum    30        31    via prote-
olytic cleavage from the neutrophil membrane which can be 
stimulated by C reactive protein, f-Met-Leu-Phe and chemo-
kines such as IL-8, leukotriene B  4   (LTB  4  ) and platelet activating 
factor.    32    There is evidence to suggest that neutrophils do not 
express the alternatively spliced version of IL-6R. Interestingly, 
in addition to IL-6, we found raised concentrations of IL-8 in 
SSc serum (see table 2 in online supplement). This has been 
reported previously, as has an increase in IL-8 in lesional skin 
by immunocytochemistry associated with early disease.    13        33–35                   
An increase in LTB  4   has also been reported in the bronchoal-
veolar lavage ﬂ  uid of patients with SSc with interstitial lung 
disease, and ﬁ  broblasts isolated from patients with SSc produce 
increased LTB  4   when stimulated in vitro.    36        37    IL-6R shedding also 
occurs when neutrophils undergo apoptosis via ADAM17.    38    
  Endothelial cell activation is reported in response to IL-6 
trans-signalling.    14        39    Given that trans-signalling blockade with 
sgp130 abrogates the effects of SSc serum on endothelial cell 
activation in co-cultures, we hypothesise that enhancement 
of trans-  signalling by local release of IL-6R from neutrophils is 
responsible for this effect. However, these data do not exclude 
neutrophil activation by trans-signalling leading to further inter-
mediates which are responsible for endothelial cell activation. 
Increased levels of sIL-6R and normal levels of sgp130 have pre-
viously been described in SSc serum.    11    
cell function in SSc. We have shown that SSc serum induces 
endothelial cell apoptosis and E-selectin expression in vitro, but 
only in the presence of neutrophils. We also provide compel-
ling evidence that IL-6 in SSc serum is responsible for these 
functional changes and propose that IL-6 trans-signalling, via 
neutrophil receptor shedding, is involved. These observations 
may thus open up new therapeutic strategies for the treatment 
of this disease. 
  These data, although important, do not conﬁ   rm that IL-6 
plays an important role in vivo. Further studies to conﬁ  rm acti-
vation of IL-6 trans-signalling pathways in lesional tissue would 
go some way to demonstrate this. In addition, the role of IL-6 
  Figure  3         Addition of interleukin 6 (IL-6) to control serum mimics the 
effects of systemic sclerosis serum. Human dermal microvascular 
endothelial cells were cultured with and without neutrophils in the 
presence of 25% heat inactivated AB serum for 24 h. As indicated, some 
cultures also contained 200 pg/ml recombinant IL-6 (rIL-6). Apoptosis 
was measured using annexin V-FITC and E-selectin expression was 
measured using an allophycocyanin-conjugated monoclonal antibody. 
Mean ﬂ  uorescence intensity (MFI) was measured by confocal 
microscopy and expressed as a fold change (±SD, n=8) corrected to 
levels in media alone (Rel MFI). rIL-6 resulted in a signiﬁ  cant increase 
in apoptosis and E-selectin expression, but only when neutrophils were 
present in the cultures.       
  Figure  4         Interleukin 6 (IL-6) depletion from systemic sclerosis (SSc) serum decreases its effects on endothelial cell activation. Human dermal 
microvascular endothelial cells were cultured with healthy control neutrophils for 24 h in the presence of 25% healthy control, SSc serum or SSc 
serum immunodepleted of IL-6 using a direct immunodepletion kit (IP). Apoptosis was measured using annexin V-FITC and E-selectin expression was 
measured using an allophycocyanin-conjugated monoclonal antibody. (A) Mean ﬂ  uorescence intensity (MFI) was measured by confocal microscopy 
and expressed as a fold change in mean ﬂ  uorescence corrected to media alone (Rel MFI) (±SD, n=8). (B) Changes in E-selectin expression in 
individual       control and SSc pairs (n=8). SSc serum resulted in signiﬁ  cantly more E-selectin expression than control serum and this effect was 
abolished by the immunodepletion of IL-6 from the SSc serum.       
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severity, and also why most patients with SSc do not exhibit the 
systemic effects of IL-6. 
  IL-6 has important effects on ﬁ  broblasts. It is a proﬁ  brotic 
cytokine that activates ﬁ  broblasts and results in an increase in 
collagen and glycosaminoglycan production.    39    An IL-6 neutralis-
ing antibody was shown to decrease procollagen 1 production in 
cultured SSc ﬁ  broblasts.    44    
  In conclusion, we hypothesise that IL-6 plays a pivotal 
role in initiating and perpetuating the chronic inﬂ  ammation, 
endothelial cell and ﬁ  broblast activation which are central to 
SSc. We have shown that SSc serum is capable of initiating 
endothelial cell apoptosis and activation in the presence of 
neutrophils. Neutrophils are the most abundant leucocytes in 
the circulation and, although they do not form a major part of 
the tissue inﬁ  ltrate in SSc, they are constantly interacting with 
the endothelial surface. We propose that, through the donation 
of sIL-6R, they may play an important role in the pathogenesis 
of SSc.     
    Funding      This work was funded by a Medical Research Council Clinical Training 
Fellowship held by TCB. The work was not in any part funded by interested parties 
in the pharmaceutical industry. The Aintree Arthritis Trust funded publication of this 
transcript.  
  IL-6 is an attractive therapeutic target in SSc. Increased levels 
of this cytokine occur in the serum of patients with SSc and 
correlate with disease activity.    8     –      12    In addition, IL-6 is increased 
in histological specimens from the lesional skin of patients with 
SSc and is associated with late disease.    13    IL-6 is spontaneously 
secreted by monocytes and ﬁ  broblasts isolated from patients 
with SSc when cultured in vitro.    40        41    It is a pleiotropic cytokine 
with many roles that may be relevant to the pathogenesis of 
this disease. 
  IL-6 seems to act as a switch from acute to chronic 
  inﬂ  ammation.    39        42        43    It may also participate in the persistence of 
chronic inﬂ  ammation as it stimulates ﬁ  broblasts and endothelial 
cells to secrete IL-6 which may then act in a paracrine fashion.    39    
It is important to point out that, although serum IL-6 levels are 
very heterogeneous in SSc, this does not mean that it does not 
play an important role in patients with relatively low serum lev-
els as it is the local concentrations of IL-6 at the cellular level 
which may be important, especially since there are pools of 
sIL-R and sgp130 in the circulation which can adsorb IL-6. The 
overall balance may depend on the lesional volume. This may 
explain why increased serum IL-6 concentrations are associated 
with the diffuse form of the disease and correlate with disease 
  Figure  6         Soluble gp130 (sgp130) decreases the effects of systemic sclerosis (SSc) serum on endothelial cell activation. Human dermal 
microvascular endothelial cells were cultured with healthy control neutrophils for 24 h in the presence of 25% healthy control or SSc serum. sgp130 
was added (500 ng/ml) to inhibit interleukin 6 trans-signalling. Apoptosis was measured using annexin V-FITC and E-selectin expression was 
measured using an allophycocyanin-conjugated monoclonal antibody. (A) Mean ﬂ  uorescence intensity (MFI) measured by confocal microscopy and 
expressed as a fold change in mean ﬂ  uorescence corrected to media alone (Rel MFI) (±SD, n=5). (B) Changes in E-selectin expression in individual 
control and SSc pairs (n=5). sgp130 signiﬁ  cantly inhibited the effect of SSc serum on apoptosis and E-selectin expression.       
  Figure  5         Neutralising interleukin 6 (IL-6) antibody decreases the effects of systemic sclerosis (SSc) serum on endothelial cell activation. Human 
dermal microvascular endothelial cells were cultured with healthy control neutrophils for 24 h in the presence of 25% healthy control or SSc serum. 
Neutralising IL-6 rabbit polyclonal antibody was added at a dilution of 1:400. Apoptosis was measured using annexin V-FITC and E-selectin expression 
was measured using an allophycocyanin-conjugated monoclonal antibody. (A) Mean ﬂ  uorescence intensity (MFI) measured by confocal microscopy 
and expressed as a fold change in mean ﬂ  uorescence corrected to media alone (Rel MFI) (±SD, n=11). (B) Changes in E-selectin expression in 
individual control and SSc pairs (n=11). The addition of neutralising IL-6 antibodies to the co-cultures resulted in a decrease in the effect of SSc 
serum towards control levels.       
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